Zobrazeno 1 - 10
of 28
pro vyhledávání: ''
Autor:
Walter E. Haefeli, Gerd Mikus, Marlene Schaumaeker, Jürgen Burhenne, Marie-Louise Lehmann, Kathrin I. Foerster
Publikováno v:
British Journal of Clinical Pharmacology
Aims Using 3 different perpetrators the impact of voriconazole, cobicistat and rifampicin (single dose), we evaluated the suitability of a microdose cocktail of factor Xa inhibitors (FXaI; rivaroxaban, apixaban and edoxaban; 100 μg in total) to stud
Autor:
Hélène M. Faessel, Xiaofei Zhou, Karthik Venkatakrishnan, Douglas V. Faller, Farhad Sedarati, Diane R. Mould
Publikováno v:
British Journal of Clinical Pharmacology
Aims A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat PK. Methods Data were pooled from 6 clinical studies consisting of 335 patients with solid tumo
Autor:
Monia Guidi, Anaïs Glatard, Chantal Csajka, Perrine Courlet, Catia Marzolini, Susana Alves Saldanha, Laurent A. Decosterd, Thierry Buclin, Matthias Cavassini, Chin B. Eap
Publikováno v:
Br J Clin Pharmacol
AIMS: The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug–drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regi
Publikováno v:
British Journal of Clinical Pharmacology. 65:326-333
What is already known about this subject • Gemcitabine is an anticancer drug which is metabolized to a number of metabolites, administered using different dosing regimens and increasingly used in combination with oxaliplatin. • The impact of dosi
Publikováno v:
British Journal of Clinical Pharmacology. 59:314-324
Aim To analyse the pharmacokinetics of melphalan in 52 children (0.3–18 years) and determine whether any clinical factors affect the pharmacokinetic parameters Additionally, to examine whether a test melphalan dose can predict the pharmacokinetics
Autor:
J. Posner, Z. Hussein
Publikováno v:
British Journal of Clinical Pharmacology. 43:457-465
Aims To examine the population pharmacokinetics of lamotrigine in patients newly diagnosed with epilepsy and receiving oral lamotrigine monotherapy for up to 48 weeks. Methods The population consisted of 158 Caucasians and 5 Asians of whom 81 were ma
Publikováno v:
British Journal of Clinical Pharmacology. 42:242-245
Clonidine is an alpha 2-adrenoceptor agonist increasingly used in combination with lignocaine for spinal or epidural anaesthesia because of a prolonged analgesic effect. Life adrenaline, it may decrease lignocaine peak concentration (Cmax), thus lead
Autor:
Giuliana Gatti, M.A. Latella, Francesco Pisani, Emilio Perucca, A. Bartoli, M. Giaccone, Roberto Marchiselli
Publikováno v:
British Journal of Clinical Pharmacology. 41:575-579
1. To assess the effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics, plasma ethosuximide concentrations after a single oral dose (500 mg) of the drug were compared in 12 healthy control subjects and 10 epileptic patients recei
Autor:
Alan V. Boddy, M. J. Tasso, L. Price, S. M. Yule, Ruth Wyllie, A. D. J. Pearson, Michael Cole, Jeffrey R. Idle
Publikováno v:
Scopus-Elsevier
1. Cyclophosphamide pharmacokinetics were measured in 38 children with cancer. 2. A high degree of inter-patient variation was seen in all pharmacokinetic parameters. Cyclophosphamide half-life varied between 1.1 and 16.8 h, clearance varied between
Autor:
Line Labbé, Catherine Litalien, Mohamad-Samer Mouksassi, Geraldine Pettersen, Yves Théorêt, Bao Nguyen, Christophe Faure
Publikováno v:
British journal of clinical pharmacology. 67(2)
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The use of intravenous pantoprazole, a proton pump inhibitor, has been increasing in the paediatric intensive care unit. • Despite this increased use, data on the disposition of intravenous pantoprazole